| News & Announcements | 10/01/2024 CPT & HCPCS Quarterly Code Update Coverage Determinations for Medicare Advantage Products | | | | | | 10/1/2024 | | | 10/01/2024 CPT & HCPCS Quarterly Code Update Coverage Determinations for Medicare Advantage Products | |
| News & Announcements | 10/01/2024 CPT & HCPCS Quarterly Code Update Coverage Determinations for Medicare Advantage Products (Updated October 8, 2024) | | | | | | 10/10/2024 | | | 10/01/2024 CPT & HCPCS Quarterly Code Update Coverage Determinations for Medicare Advantage Products (Updated October 8, 2024) | |
| News & Announcements | Preventive Coverage of Pre-exposure Prophylaxis for the Prevention of HIV Infection (Retroactively Effective September 30, 2024) | | | | | | 10/14/2024 | | | Preventive Coverage of Pre-exposure Prophylaxis for the Prevention of HIV Infection (Retroactively Effective September 30, 2024) | |
| Notifications | Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors | MA08.073q | 10/8/2024 9:00 AM | 1/1/2025 | | | 10/8/2024 | Medical Necessity Criteria | | Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors | |
| Notifications | Luspatercept–aamt (Reblozyl®) | MA08.110d | 10/22/2024 11:00 AM | 1/17/2025 | | | 10/22/2024 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | Luspatercept–aamt (Reblozyl®) | |
| New Policies | Lifileucel (Amtagvi™) | MA08.172 | | 10/21/2024 | | | 10/21/2024 | This is a New Policy. | | Lifileucel (Amtagvi™) | |
| Updated Policies | Sacral Nerve Stimulation (SNS) and Posterior Tibial Nerve Stimulation (PTNS) for the Control of Incontinence | MA11.028k | | 10/1/2024 | | | 10/1/2024 | Medical Necessity Criteria;Medical Coding | | Sacral Nerve Stimulation (SNS) and Posterior Tibial Nerve Stimulation (PTNS) for the Control of Incontinence | |
| Updated Policies | Tocilizumab (Actemra®) and Related Biosimilars for Intravenous Infusion and Subcutaneous Injection | MA08.045l | | 10/1/2024 | | | 10/7/2024 | Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | Tocilizumab (Actemra®) and Related Biosimilars for Intravenous Infusion and Subcutaneous Injection | |
| Updated Policies | Rituximab (Rituxan®) Infusion and Related Biosimilars, and Rituximab/Hyaluronidase Human for Subcutaneous Injection (Rituxan Hycela®) | MA08.022r | | 10/7/2024 | | | 10/7/2024 | Medical Necessity Criteria;Medical Coding | | Rituximab (Rituxan®) Infusion and Related Biosimilars, and Rituximab/Hyaluronidase Human for Subcutaneous Injection (Rituxan Hycela®) | |
| Updated Policies | Efgartigimod alfa - fcab (Vyvgart) and efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo) | MA08.142d | | 10/7/2024 | | | 10/7/2024 | Medical Necessity Criteria;Medical Coding | | Efgartigimod alfa - fcab (Vyvgart) and efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo) | |
| Updated Policies | Sacituzumab govitecan-hziy (Trodelvy™) | MA08.118f | | 10/7/2024 | | | 10/7/2024 | Medical Necessity Criteria | | Sacituzumab govitecan-hziy (Trodelvy™) | |
| Updated Policies | Risankizumab-rzaa (Skyrizi®) for intravenous use | MA08.153c | | 10/21/2024 | | | 10/21/2024 | Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | Risankizumab-rzaa (Skyrizi®) for intravenous use | |
| Updated Policies | Trilaciclib (Cosela™) | MA08.134e | | 10/21/2024 | | | 10/21/2024 | Medical Necessity Criteria | | Trilaciclib (Cosela™) | |
| Updated Policies | Percutaneous Coronary Intervention, Coronary Angiography, and Arterial Ultrasound | MA11.113i | | 10/20/2024 | | | 10/21/2024 | Medical Coding;General Description, Guidelines, or Informational Update | | Percutaneous Coronary Intervention, Coronary Angiography, and Arterial Ultrasound | |
| Updated Policies | High-Technology Radiology Services | MA09.002ac | | 10/20/2024 | | | 10/21/2024 | General Description, Guidelines, or Informational Update | | High-Technology Radiology Services | |
| Updated Policies | Sleep Disorder Testing and Positive Airway Pressure Therapy Services and Supplies | MA07.058l | | 10/20/2024 | | | 10/21/2024 | Coverage and/or Reimbursement Position;Medical Necessity Criteria | | Sleep Disorder Testing and Positive Airway Pressure Therapy Services and Supplies | |
| Updated Policies | Musculoskeletal Services | MA00.047m | | 10/20/2024 | | | 10/21/2024 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;Medical Coding | | Musculoskeletal Services | |
| Updated Policies | Balloon Catheter Dilation of Sinus Ostia for Treatment of Chronic Rhinosinusitis or Recurrent Acute Rhinosinusitis | MA11.100f | | 10/21/2024 | | | 10/21/2024 | Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | Balloon Catheter Dilation of Sinus Ostia for Treatment of Chronic Rhinosinusitis or Recurrent Acute Rhinosinusitis | |
| Updated Policies | Interleukin-5 (IL-5) Antagonist (e.g., Cinqair®, Nucala®) and IL-5 Receptor Antagonist (e.g., Fasenra®) | MA08.024l | | 10/21/2024 | | | 10/21/2024 | Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | Interleukin-5 (IL-5) Antagonist (e.g., Cinqair®, Nucala®) and IL-5 Receptor Antagonist (e.g., Fasenra®) | |
| Updated Policies | patisiran (Onpattro®) and vutrisiran (Amvuttra®) | MA08.100d | | 10/21/2024 | | | 10/21/2024 | Medical Necessity Criteria | | patisiran (Onpattro®) and vutrisiran (Amvuttra®) | |
| Reissue Policies | Procedures for the Treatment of Gastroesophageal Reflux Disease (GERD) | MA11.055f | | 1/2/2023 | 10/2/2024 | | 10/2/2024 | | | Procedures for the Treatment of Gastroesophageal Reflux Disease (GERD) | |
| Reissue Policies | Loncastuximab tesirine-lpyl (Zynlonta®) | MA08.139c | | 1/1/2024 | 10/2/2024 | | 10/2/2024 | | | Loncastuximab tesirine-lpyl (Zynlonta®) | |
| Reissue Policies | Chemical Peels | MA11.103b | | 12/26/2022 | 10/2/2024 | | 10/2/2024 | | | Chemical Peels | |
| Reissue Policies | Procedures for the Treatment of Acne | MA11.109a | | 10/1/2016 | 10/2/2024 | | 10/2/2024 | | | Procedures for the Treatment of Acne | |
| Reissue Policies | Selective Photothermolysis Using Pulsed-Dye Lasers (PDL) | MA11.071b | | 7/11/2022 | 10/2/2024 | | 10/2/2024 | | | Selective Photothermolysis Using Pulsed-Dye Lasers (PDL) | |
| Reissue Policies | Neuropsychological Testing for Neurologically Based Conditions | MA07.038k | | 10/1/2023 | 10/16/2024 | | 10/16/2024 | | | Neuropsychological Testing for Neurologically Based Conditions | |
| Reissue Policies | STAT Laboratory Tests Performed in the Outpatient Hospital Setting for Health Maintenance Organization (HMO) and Point-of-Service (POS) Products | MA00.021b | | 1/1/2021 | 10/16/2024 | | 10/16/2024 | | | STAT Laboratory Tests Performed in the Outpatient Hospital Setting for Health Maintenance Organization (HMO) and Point-of-Service (POS) Products | |
| Reissue Policies | Day Rehabilitation | MA10.005b | | 1/1/2024 | 10/16/2024 | | 10/16/2024 | | | Day Rehabilitation | |
| Reissue Policies | Tumor Treating Fields | MA07.032 | | 9/1/2019 | 10/16/2024 | | 10/16/2024 | | | Tumor Treating Fields | |
| Reissue Policies | Hyaluronan Acid Therapies for Osteoarthritis of the Knee | MA11.023k | | 1/1/2024 | 10/16/2024 | | 10/16/2024 | | | Hyaluronan Acid Therapies for Osteoarthritis of the Knee | |
| Reissue Policies | Catheter Ablation of Cardiac Arrhythmias | MA11.060g | | 1/1/2024 | 10/16/2024 | | 10/16/2024 | | | Catheter Ablation of Cardiac Arrhythmias | |
| Reissue Policies | Upper Gastrointestinal Endoscopy (Diagnostic and Therapeutic) | MA07.023k | | 1/2/2024 | 10/16/2024 | | 10/16/2024 | | | Upper Gastrointestinal Endoscopy (Diagnostic and Therapeutic) | |
| Reissue Policies | Drug-Eluting Beads and Bland Embolization for the Treatment of Hepatic Malignancies | MA07.041c | | 10/1/2024 | 10/30/2024 | | 10/30/2024 | | | Drug-Eluting Beads and Bland Embolization for the Treatment of Hepatic Malignancies | |
| Reissue Policies | Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI) | MA07.004h | | 10/1/2024 | 10/30/2024 | | 10/30/2024 | | | Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI) | |
| Reissue Policies | Coverage of Medical Devices | MA05.040b | | 11/4/2019 | 10/30/2024 | | 10/30/2024 | | | Coverage of Medical Devices | |
| Reissue Policies | Durable Medical Equipment (DME) Not Subject to a Rental to Purchase Maximum | MA05.028e | | 1/18/2021 | 10/30/2024 | | 10/30/2024 | | | Durable Medical Equipment (DME) Not Subject to a Rental to Purchase Maximum | |
| Reissue Policies | Insertion of Implantable Infusion Pumps | MA05.053n | | 10/1/2024 | 10/30/2024 | | 10/30/2024 | | | Insertion of Implantable Infusion Pumps | |
| Reissue Policies | Pulmonary Rehabilitation | MA10.001c | | 1/1/2024 | 10/30/2024 | | 10/30/2024 | | | Pulmonary Rehabilitation | |
| Reissue Policies | Eptinezumab-jjmr (VYEPTI™) | MA08.116d | | 1/1/2024 | 10/30/2024 | | 10/30/2024 | | | Eptinezumab-jjmr (VYEPTI™) | |
| Reissue Policies | Scar Revision | MA11.078c | | 12/19/2022 | 10/30/2024 | | 10/30/2024 | | | Scar Revision | |
| Reissue Policies | In Vitro Allergy Testing | MA06.002c | | 1/1/2024 | 10/30/2024 | | 10/30/2024 | | | In Vitro Allergy Testing | |
| Reissue Policies | Nebulizers and Inhalation Solutions | MA05.007f | | 1/1/2024 | 10/30/2024 | | 10/30/2024 | | | Nebulizers and Inhalation Solutions | |
| Reissue Policies | Lurbinectedin (Zepzelca®) | MA08.125c | | 5/8/2023 | 10/30/2024 | | 10/30/2024 | | | Lurbinectedin (Zepzelca®) | |
| Reissue Policies | Sutimlimab-jome (Enjaymo) | MA08.145a | | 1/1/2024 | 10/30/2024 | | 10/30/2024 | | | Sutimlimab-jome (Enjaymo) | |
| Reissue Policies | Treatment of Pulmonary Artery Hypertension with Intravenous, Subcutaneous, and Inhaled Pharmacologic Agents | MA08.016g | | 1/1/2024 | 10/30/2024 | | 10/30/2024 | | | Treatment of Pulmonary Artery Hypertension with Intravenous, Subcutaneous, and Inhaled Pharmacologic Agents | |
| Reissue Policies | Polatuzumab vedotin-piiq (Polivy®) | MA08.108e | | 1/1/2024 | 10/30/2024 | | 10/30/2024 | | | Polatuzumab vedotin-piiq (Polivy®) | |
| Reissue Policies | In Vivo Allergy Sensitivity Testing | MA06.004c | | 1/1/2024 | 10/30/2024 | | 10/30/2024 | | | In Vivo Allergy Sensitivity Testing | |
| Reissue Policies | Ultraviolet Light Therapy for the Treatment of Dermatological Conditions | MA07.002i | | 10/1/2024 | 10/30/2024 | | 10/30/2024 | | | Ultraviolet Light Therapy for the Treatment of Dermatological Conditions | |
| Reissue Policies | Pain Management of Peripheral Nerves by Injection | MA07.047h | | 12/27/2021 | 10/30/2024 | | 10/30/2024 | | | Pain Management of Peripheral Nerves by Injection | |
| Reissue Policies | Power Wheelchairs (PWCs), Power-Operated Vehicles (POVs), and Push-Rim-Activated Power-Assist Devices Policy #MA05.032c | MA05.032c | | 1/1/2024 | 10/30/2024 | | 10/30/2024 | | | Power Wheelchairs (PWCs), Power-Operated Vehicles (POVs), and Push-Rim-Activated Power-Assist Devices Policy #MA05.032c | |
| Coding Update | Ultraviolet Light Therapy for the Treatment of Dermatological Conditions | MA07.002i | | 10/1/2024 | | | 10/1/2024 | | | Ultraviolet Light Therapy for the Treatment of Dermatological Conditions | |
| Coding Update | Treatment of Medical and Surgical Complications | MA11.050c | | 10/1/2024 | | | 10/1/2024 | | | Treatment of Medical and Surgical Complications | |
| Coding Update | Vagus Nerve Stimulation (VNS) | MA11.019l | | 10/1/2024 | | | 10/1/2024 | | | Vagus Nerve Stimulation (VNS) | |
| Coding Update | Brentuximab Vedotin (Adcetris®) | MA08.068j | | 10/1/2024 | | | 10/1/2024 | | | Brentuximab Vedotin (Adcetris®) | |
| Coding Update | Epcoritamab-bysp (EPKINLY™) | MA08.165a | | 10/1/2024 | | | 10/1/2024 | | | Epcoritamab-bysp (EPKINLY™) | |
| Coding Update | Prescription Digital Therapeutics and Mobile-Based Health Management Applications | MA12.011c | | 10/1/2024 | | | 10/1/2024 | | | Prescription Digital Therapeutics and Mobile-Based Health Management Applications | |
| Coding Update | Hair Transplants and Cranial Prostheses (Wigs) | MA11.046c | | 10/1/2024 | 10/1/2024 | | 10/1/2024 | | | Hair Transplants and Cranial Prostheses (Wigs) | |
| Coding Update | Home Prothrombin Time Monitoring | MA05.016i | | 10/1/2024 | 10/1/2024 | | 10/1/2024 | | | Home Prothrombin Time Monitoring | |
| Coding Update | Knee Orthoses | MA05.013i | | 10/1/2024 | 10/1/2024 | | 10/1/2024 | | | Knee Orthoses | |
| Coding Update | Transcutaneous Electrical Nerve Stimulators (TENS) and Associated Supplies | MA05.006j | | 10/1/2024 | 10/1/2024 | | 10/1/2024 | | | Transcutaneous Electrical Nerve Stimulators (TENS) and Associated Supplies | |
| Coding Update | Carfilzomib (Kyprolis) | MA08.062i | | 10/1/2024 | | | 10/1/2024 | | | Carfilzomib (Kyprolis) | |
| Coding Update | External Infusion Pumps | MA05.060c | | 10/1/2024 | | | 10/1/2024 | | | External Infusion Pumps | |
| Coding Update | Pulmonary Function Tests | MA07.007o | | 10/1/2024 | | | 10/1/2024 | | | Pulmonary Function Tests | |
| Coding Update | Continuous Glucose Monitors and Home Blood Glucose Monitors and Supplies | MA00.002p | | 10/1/2024 | | | 10/1/2024 | | | Continuous Glucose Monitors and Home Blood Glucose Monitors and Supplies | |
| Coding Update | Anesthesia Services for Epidural, Paravertebral Facet and Sacroiliac Joint Injections for Spinal Joint Management | MA01.008c | | 10/1/2024 | | | 10/1/2024 | | | Anesthesia Services for Epidural, Paravertebral Facet and Sacroiliac Joint Injections for Spinal Joint Management | |
| Coding Update | Upper Gastrointestinal Endoscopy (Diagnostic and Therapeutic) | MA07.023k | | 10/1/2024 | | | 10/1/2024 | | | Upper Gastrointestinal Endoscopy (Diagnostic and Therapeutic) | |
| Coding Update | Nivolumab (Opdivo®) | MA08.120d | | 10/1/2024 | | | 10/1/2024 | | | Nivolumab (Opdivo®) | |
| Coding Update | Dermabrasion for Rhinophyma, Septoplasty, Rhinoplasty, and Septorhinoplasty | MA11.099e | | 10/1/2024 | | | 10/1/2024 | | | Dermabrasion for Rhinophyma, Septoplasty, Rhinoplasty, and Septorhinoplasty | |
| Coding Update | Drug-Eluting Beads and Bland Embolization for the Treatment of Hepatic Malignancies | MA07.041c | | 10/1/2024 | | | 10/1/2024 | | | Drug-Eluting Beads and Bland Embolization for the Treatment of Hepatic Malignancies | |
| Coding Update | Panniculectomy, Abdominoplasty, Abdominal Lipectomy, and Other Excisions of Redundant Skin | MA11.073e | | 10/1/2024 | | | 10/1/2024 | | | Panniculectomy, Abdominoplasty, Abdominal Lipectomy, and Other Excisions of Redundant Skin | |
| Coding Update | Speech and Non-Speech Generating Devices | MA05.003g | | 10/1/2024 | | | 10/1/2024 | | | Speech and Non-Speech Generating Devices | |
| Coding Update | Transcatheter Arterial Chemoembolization (TACE) of Hepatic Malignancies | MA07.040c | | 10/1/2024 | | | 10/1/2024 | | | Transcatheter Arterial Chemoembolization (TACE) of Hepatic Malignancies | |
| Coding Update | Octreotide Acetate (Sandostatin® LAR Depot) | MA08.065j | | 10/1/2024 | | | 10/1/2024 | | | Octreotide Acetate (Sandostatin® LAR Depot) | |
| Coding Update | Autonomic Nervous System Testing | MA07.027g | | 10/1/2024 | | | 10/1/2024 | | | Autonomic Nervous System Testing | |
| Coding Update | Teplizumab-mzwv (Tzield) | MA08.157a | | 10/1/2024 | | | 10/1/2024 | | | Teplizumab-mzwv (Tzield) | |
| Coding Update | Treatments for Complex Regional Pain Syndrome (CRPS) | MA08.026k | | 10/1/2024 | | | 10/1/2024 | | | Treatments for Complex Regional Pain Syndrome (CRPS) | |
| Coding Update | Omalizumab (Xolair®) | MA08.025f | | 10/1/2024 | | | 10/1/2024 | | | Omalizumab (Xolair®) | |
| Coding Update | Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG) | MA08.009v | | 10/1/2024 | | | 10/1/2024 | | | Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG) | |
| Coding Update | Tafasitamab-cxix (Monjuvi®) | MA08.138d | | 10/1/2024 | | | 10/1/2024 | | | Tafasitamab-cxix (Monjuvi®) | |
| Coding Update | Asparaginase erwinia chrysanthemi (Erwinaze®), asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze®) | MA08.085h | | 10/1/2024 | | | 10/1/2024 | | | Asparaginase erwinia chrysanthemi (Erwinaze®), asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze®) | |
| Coding Update | Chimeric Antigen Receptor (CAR) Therapy | MA08.093n | | 10/1/2024 | | | 10/1/2024 | | | Chimeric Antigen Receptor (CAR) Therapy | |
| Coding Update | Denosumab (Prolia®, Xgeva®), Romosozumab-aqqg (Evenity®) | MA08.052m | | 10/1/2024 | | | 10/1/2024 | | | Denosumab (Prolia®, Xgeva®), Romosozumab-aqqg (Evenity®) | |
| Coding Update | Glofitamab-gxbm (Columvi) | MA08.163c | | 10/1/2024 | | | 10/1/2024 | | | Glofitamab-gxbm (Columvi) | |
| Coding Update | Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use | MA08.072n | | 10/1/2024 | | | 10/1/2024 | | | Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use | |
| Coding Update | Lanreotide (Somatuline® Depot) | MA08.090g | | 10/1/2024 | | | 10/1/2024 | | | Lanreotide (Somatuline® Depot) | |
| Coding Update | Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)/(Abraxane® for Injectable Suspension) | MA08.049n | | 10/1/2024 | | | 10/1/2024 | | | Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)/(Abraxane® for Injectable Suspension) | |
| Coding Update | Pembrolizumab (Keytruda®) | MA08.121e | | 10/1/2024 | | | 10/1/2024 | | | Pembrolizumab (Keytruda®) | |
| Coding Update | Pemetrexed (Pemfexy™) | MA08.047l | | 10/1/2024 | | | 10/1/2024 | | | Pemetrexed (Pemfexy™) | |
| Coding Update | Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI) | MA07.004h | | 10/1/2024 | | | 10/1/2024 | | | Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI) | |
| Coding Update | Insertion of Implantable Infusion Pumps | MA05.053n | | 10/1/2024 | | | 10/1/2024 | | | Insertion of Implantable Infusion Pumps | |
| Coding Update | Photodynamic Therapy Using Verteporfin (Visudyne®) | MA07.003e | | 10/1/2024 | | | 10/1/2024 | | | Photodynamic Therapy Using Verteporfin (Visudyne®) | |
| Coding Update | Wound Care: Skin Substitutes for the Treatment of Burns and Chronic, Non-Healing Wounds | MA11.015aa | | 10/1/2024 | | | 10/1/2024 | | | Wound Care: Skin Substitutes for the Treatment of Burns and Chronic, Non-Healing Wounds | |
| Coding Update | Preventive Care Services | MA00.003aa | | 10/1/2024 | | | 10/2/2024 | | | Preventive Care Services | |
| Coding Update | Modifier 62: Two Surgeons | MA00.011t | | 10/1/2024 | | | 10/4/2024 | | | Modifier 62: Two Surgeons | |
| Coding Update | Modifiers for Assistant-at-Surgery Services: 80, 81, 82, and AS | MA00.015r | | 10/1/2024 | | | 10/4/2024 | | | Modifiers for Assistant-at-Surgery Services: 80, 81, 82, and AS | |
| Coding Update | Modifier 25: Significant, Separately Identifiable Evaluation and Management Service by the Same Physician or Other Qualified Health Care Professional on the Same Day of the Procedure or Other Service | MA03.003o | | 10/1/2024 | | | 10/4/2024 | | | Modifier 25: Significant, Separately Identifiable Evaluation and Management Service by the Same Physician or Other Qualified Health Care Professional on the Same Day of the Procedure or Other Service | |
| Coding Update | Medicare Part B vs. Part D Crossover Drugs | MA08.007ao | | 10/1/2024 | | | 10/7/2024 | | | Medicare Part B vs. Part D Crossover Drugs | 10/7/2024 |
| Coding Update | Medicare Part B vs. Part D Crossover Drugs | MA08.007ao | | 10/1/2024 | | | 10/8/2024 | | | Medicare Part B vs. Part D Crossover Drugs | |
| Coding Update | Magnetic Resonance Imaging (MRI) Contrast Agents | MA09.010f | | 10/1/2024 | | | 10/9/2024 | | | Magnetic Resonance Imaging (MRI) Contrast Agents | |
| Coding Update | Durable Medical Equipment (DME) | MA05.044r | | 10/1/2024 | | | 10/10/2024 | | | Durable Medical Equipment (DME) | |
| Coding Update | Repair and Replacement of Durable Medical Equipment (DME) and Prosthetic Devices | MA05.062k | | 10/1/2024 | | | 10/10/2024 | | | Repair and Replacement of Durable Medical Equipment (DME) and Prosthetic Devices | |
| Coding Update | Always Bundled Procedure Codes | MA00.026v | | 10/1/2024 | | | 10/15/2024 | | | Always Bundled Procedure Codes | |
| Coding Update | PPO Network Rules for Provision of Specialty Services for Durable Medical Equipment and Laboratory, Radiology, and Physical Medicine and Rehabilitative Services | MA00.010aq | | 10/1/2024 | | | 10/16/2024 | | | PPO Network Rules for Provision of Specialty Services for Durable Medical Equipment and Laboratory, Radiology, and Physical Medicine and Rehabilitative Services | |
| Coding Update | Reimbursement for Radiopharmaceutical Agents for Professional Providers | MA09.009u | | 10/1/2024 | | | 10/28/2024 | | | Reimbursement for Radiopharmaceutical Agents for Professional Providers | |
| Archived Policies | Transcatheter Closure of Cardiac Septal Defects | MA11.040c | 10/18/2024 11:00 AM | 11/18/2024 | | | 10/18/2024 | | | Transcatheter Closure of Cardiac Septal Defects | |